Please find here an overview of guidance documents currently under development, either proposed or endorsed by ESCMID or its study groups.

The status of each project is defined based on the steps of the GIN-McMaster Guideline Development Checklist.

For more information please contact us at guidancedocuments[at]escmid.org.

  • Approach to suspected antibiotic allergy

 

Chair: Mark de Boer

 

Approval date: January 2023

 

Satus (date): Deciding what Evidence to Include and Searching for Evidence (September 2023)

 

  • Vaccination of the immunocompromised host

 

Chair: Olivier Epaulard

 

Approval date: January 2023

 

Satus (date): Deciding what Evidence to Include and Searching for Evidence (September 2023)

 

  • Dosing of antimicrobials in patient with renal impairment with or without RRT

 

Chair: Thomas Tängdén

 

Approval date: January 2023

 

Satus (date): Deciding what Evidence to Include and Searching for Evidence (September 2023)

 

  • ESCMID Consensus document for management of COVID-19 in immunocompromised patients

 

Chair: Michele Bartoletti

 

Approval date: May 2022

 

Satus (date): Deciding what Evidence to Include and Searching for Evidence (October 2023)

 

  • the Update of the 2014 ESCMID guidelines for the management of the infection prevention & control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients (ESCMID)

 

Chair: Evelina Tacconelli

 

Approval date: December 2020

 

Status (date): Deciding what Evidence to Include and Searching for Evidence (September 2023)

 

  • Antibiotic surgical prophylaxis regimens among patients colonised by MDR-GPB (ESCMID)

 

Chair: Nico T. Mutters

 

Approval date: December 2019

 

Status (date): Deciding what Evidence to Include and Searching for Evidence (September 2023)

 

  • Antimicrobial stewardship in the emergency department (ESCMID)

 

Chair: Jeroen Schouten

 

Approval date: December 2019

 

Status (date): Developing Recommendations and Determining their Strength (November 2023)

 

  • Influenza management and treatment (ESCMID)

 

Chair: Barbara Rath

 

Approval date: December 2019

 

Status (date): Deciding what Evidence to Include and Searching for Evidence (September 2023)

 

  • Management of uncomplicated urinary tract infections (IDSA/ESCMID)

 

ESCMID representative: Angela Huttner

 

Approval date: April 2019

 

Status (date): Deciding what evidence to include and searching for evidence (October 2022)

 

  • Microbiological diagnosis of bloodstream infections (ESCMID/ESA)

 

Chair: Brigitte Lamy

 

Approval date: November 2018

 

Status (date): Deciding what Evidence to Include and Searching for Evidence (November 2023)

 

  • Diagnosis and management of infective encephalitis (ESCMID/EAN)

 

ESCMID representative: Thomas Whitfield

 

Approval date: April 2018

 

Status (date): Deciding what evidence to include and searching for evidence (October 2022)

 

  • Management of Staphylococcus aureus bacteremia (IDSA/ESCMID)

 

ESCMID representative: Winfried Kern & François Vandenesch.

 

Approval date: January 2017

 

Status (date): Deciding what evidence to include and searching for evidence (September 2022)